Validation of Stroke Volume Measurement by a New Noninvasive Hemodynamic Monitoring System (NexFin)in Comparison to Different Invasive Procedures as Picco2, FloTrac and TEE (VaSNex)
Status
Conditions
Treatments
Details and patient eligibility
About
Main hypothesis: there is no difference between stroke volume measurements recorded by a new noninvasive finger cuff system (NexFin) and invasive hemodynamic monitoring systems as Picco2-system, FloTrac and transesophageal echocardiography
Full description
In high risc patients undergoing orthopedic surgery an extended cardiopulmonary observation improves patients safety and postoperative outcome. Therefore invasive procedures as Picco2-system, FloTrac and transesophageal echocardiography (tee) have the advantage to measure or calculate stroke volume. Disadvantage of this treatments is the need for a vascular access with all its complications.
In this study the stroke volume measured by a new noninvasive finger cuff system (NexFin) should be validated in comparison to invasive hemodynamic monitoring systems as Picco2-system, FloTrac and tee.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- patients undergoing orthopedic surgery with need for invasive blood pressure measurements
- age ≥ 18 years
- signed informed consent
- no participation on another interventional study
Exclusion criteria
- refusal of participation
- patients who are not able to sign informed consent
- atrial fibrillation with arrhythmia
- peripheral arterial disease > Fontain IIa
- scleroderma
- presence of an arterio-venous shunt on upper limb
- contraindication for femoral arterial vascular access
- contraindication for transesophageal echocardiography
- stage III heart valve defects
- shunt heart defects
- solitary regional anaesthesia
- pregnant or breastfeeding women
Trial design
Primary purpose
Allocation
Interventional model
Masking
20 participants in 1 patient group
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal